

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MERCK SHARP & DOHME LLC,
Petitioner

v.

HALOZYME INC.,
Patent Owner

Case PGR2025-00017
U.S. Patent No. 12,110,520

PATENT OWNER'S MOTION FOR ADDITIONAL DISCOVERY

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I. INTRODUCTION: DISCOVERY IS WARRANTED..... 1

II. BACKGROUND: PETITIONER HAS REFUSED TO PROVIDE UNREDACTED VERSIONS OF RELEVANT DOCUMENTS 3

III. ARGUMENT: PETITIONER SHOULD PROVIDE UNREDACTED VERSIONS OF ALL DOCUMENTS..... 4

 A. HALOZYME’S DISCOVERY REQUESTS SATISFY THE *GARMIN* FACTORS AND GOOD CAUSE EXISTS FOR THE REQUESTED DISCOVERY8

 1. *Garmin* Factor 1: More Than a Possibility And Mere Allegation that Useful Information Will Be Found..... 8

 2. *Garmin* Factor 2: No Request for Litigation Positions and Underlying Basis..... 10

 3. *Garmin* Factor 3: No Ability To Generate Equivalent Information By Other Means 10

 4. *Garmin* Factors 4 and 5: Requests Are Easily Understandable and Not Overly Burdensome To Answer 10

IV. CONCLUSION..... 10

PATENT OWNER'S UPDATED EXHIBIT LIST

Ex. No.	Description
2001	Declaration of Barbara Triggs-Raine, Ph.D. in support of Patent Owner Discretionary Denial Brief (WITHDRAWN)
2002	<i>Curriculum Vitae</i> of Barbara Triggs-Raine, Ph.D.
2003	Disclaimer in a Patent under 37 C.F.R. § 1.321(a), filed in U.S. Patent Application No. 18/068,418, May 7, 2025
2004	“Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCIASCO Annual Meeting,” Halozyme Therapeutics, Inc. Press Release, October 24, 2011
2005	LinkedIn profiles of Michael Shepard, Robert Connor, Ge (Gina) Wei, and Qiping Zhao
2006	Sequence listing of U.S. Patent Application No. 18/068,418
2007	Gifre, L., et al., “Trends in recombinant protein use in animal production,” <i>Microb Cell Fact</i> 16:40 (2017)
2008	“Recombinant Drugs,” Smithsonian Institution, accessible at https://www.si.edu/spotlight/birth-of-biotech/recombinant-drugs (last accessed February 27, 2025)
2009	Naz, R., “Antisperm Contraceptive Vaccines: Where We Are and Where We Are Going?,” <i>American Journal of Reproductive Immunology</i> 66:5-12 (2011)
2010	Primakoff, P., et al., “Fully effective contraception in male and female guinea pigs immunized with the sperm protein PH-20,” <i>Nature</i> 335:543-546 (October 6, 1988)
2011	Definition of “guinea pig,” Merriam-Webster OnLine, archived by the Internet Archive on February 21, 2010, accessible at https://web.archive.org/web/20100221175034/http://www.merriam-webster.com/dictionary/guinea%20pig (last accessed February 27, 2025)

Ex. No.	Description
2012	“A decade in numbers,” <i>Nature Materials</i> 11:743-744 (September 2012)
2013	Lin, Y., <i>et al.</i> , “Molecular cloning of the human and monkey sperm surface protein PH-20,” <i>Proc. Natl. Acad. Sci USA</i> 90:10071-10075 (November 1993)
2014	<i>Intentionally Left Blank</i>
2015	File History of U.S. Patent No. 7,872,107
2016	Pils, B., <i>et al.</i> , “Variation in structural location and amino acid conservation of functional sites in protein domain families,” <i>BMC Bioinformatics</i> 6 (August 25, 2005)
2017	<i>Intentionally Left Blank</i>
2018	Duterme, C., <i>et al.</i> , “Two Novel Functions of Hyaluronidase-2 (Hyal2) Are Formation of the Glycocalyx and Control of CD44-ERM Interactions,” <i>The Journal of Biological Chemistry</i> , 284(48):33495-33508 (November 27, 2009)
2019	Atmuri, V., <i>et al.</i> , “Hyaluronidase 3 (<i>HYAL3</i>) knockout mice do not display evidence of hyaluronan accumulation,” <i>Matrix Biology</i> 27 (2008)
2020	Hemming, R., <i>et al.</i> , “Mouse Hyal3 encodes a 45- to 56-kDa glycoprotein whose overexpression increases hyaluronidase 1 activity in cultured cells,” <i>Glycobiology</i> 18(4):280-289 (2008)
2021	Miller, A., “Hyaluronidase 2 and its intriguing role as a cell-entry receptor for oncogenic sheep retroviruses,” <i>Seminars in Cancer Biology</i> 18:296-301 (2008)
2022	Kaneiwa, T. <i>et al.</i> , “Identification of human hyaluronidase-4 as a novel chondroitin sulfate hydrolase that preferentially cleaves the galactosaminidic linkage in the trisulfated tetrasaccharide sequence,” <i>Glycobiology</i> 20(3):300-309 (March 2010)

Ex. No.	Description
2023	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00004 (P.T.A.B.), November 26, 2024
2024	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00003 (P.T.A.B.), November 12, 2024
2025	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00009 (P.T.A.B.), December 27, 2024
2026	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00006 (P.T.A.B.), December 10, 2024
2027	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00030 (P.T.A.B.), February 4, 2025
2028	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00024 (P.T.A.B.), February 21, 2025
2029	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00004 (P.T.A.B.), November 26, 2024
2030	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00003 (P.T.A.B.), November 12, 2024
2031	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00009 (P.T.A.B.), December 27, 2024
2032	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00006 (P.T.A.B.), December 10, 2024

Ex. No.	Description
2033	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00030 (P.T.A.B.), February 4, 2025
2034	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00024 (P.T.A.B.), February 21, 2025
2035	Lokeshwar, V., <i>et al.</i> , “Regulation of Hyaluronidase Activity by Alternative mRNA Splicing,” <i>The Journal of Biological Chemistry</i> 277(37):33654-33663 (2002)
2036	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00033 (P.T.A.B.), March 7, 2025
2037	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00033 (P.T.A.B.), March 7, 2025
2038	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00039 (P.T.A.B.), March 28, 2025
2039	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00039 (P.T.A.B.), March 28, 2025
2040-2045	<i>Intentionally Left Blank</i>
2046	“2023 Pharma 50: The 50 largest pharma companies in the world,” drugdiscoverytrends.com, accessible at https://www.drugdiscoverytrends.com/2023-pharma-50-largest-companies/ (last accessed April 28, 2025)
2047	“Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results,” Merck Press Release, February 4, 2025
2048	“Products list,” Merck.com, accessible at https://www.merck.com/products/ (last accessed April 28, 2025)
2049	<i>Intentionally Left Blank</i>

Ex. No.	Description
2050	“Merck & Company, Inc. Common Stock (new) (MRK),” Nasdaq.com, accessible at https://www.nasdaq.com/market-activity/stocks/mrk (last accessed April 28, 2025)
2051	“Halozyme Therapeutics, Inc. Common Stock (HALO),” Nasdaq.com, accessible at https://www.nasdaq.com/market-activity/stocks/halo (last accessed April 28, 2025)
2052	“Halozyme reports full year 2024 record revenue of \$1.015 billion and Exceeds its Financial Guidance for Royalty Revenue, Adjusted EBITDA and Non-GAAP Diluted EPS,” Halozyme.com, accessible at https://ir.halozyme.com/news/news-details/2025/HALOZYME-REPORTS-FULL-YEAR-2024-RECORD-REVENUE-OF-1.015-BILLION-AND-EXCEEDS-ITS-FINANCIAL-GUIDANCE-FOR-ROYALTY-REVENUE-ADJUSTED-EBITDA-AND-NON-GAAP-DILUTED-EPS/default.aspx (last accessed April 28, 2025)
2053	“Commercial Products,” Halozyme.com, accessible at https://halozyme.com/commercial-products/ (last accessed April 28, 2025)
2054	“About Us,” Halozyme.com, accessible at https://halozyme.com/about-us/#our-focus (last accessed April 28, 2025)
2055	Second Declaration of Barbara Triggs-Raine, Ph.D. in Support of Patent Owner’s Preliminary Response (WITHDRAWN)
2056	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00042 (P.T.A.B.), April 15, 2025
2057	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00042 (P.T.A.B.), April 15, 2025
2058	Complaint for Patent Infringement and Declaratory Judgment of Patent Infringement, <i>Halozyme, Inc. v. Merck Sharp & Dohme Corp.</i> , Civil Action No. 2:25-cv-03179-ES (D.N.J.), filed April 24, 2025

Ex. No.	Description
2059	“Alteogen announces amendment to license agreement with MSD,” Alteogen Press Release, February 22, 2025, accessible at https://www.alteogen.com/en/ir_1/?uid=2223&mod=document&pageid=1 (last accessed April 28, 2025)
2060	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00046 (P.T.A.B.), April 29, 2025
2061	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00046 (P.T.A.B.), April 29, 2025
2062	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00050 (P.T.A.B.), May 7, 2025
2063	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00050 (P.T.A.B.), May 7, 2025
2064	Petition for Post-Grant Review, <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00053 (P.T.A.B.), June 6, 2025
2065	Declaration of Michael Hecht, Ph.D. (Exhibit 1003), <i>Merck Sharp & Dohme LLC v. Halozyme Inc.</i> , Case No. PGR2025-00053 (P.T.A.B.), June 6, 2025
2066	Declaration of Tyler C. Liu (<i>served not filed</i>)
2067	<i>Intentionally left blank</i>
2068	Declaration of Melanie A. Simpson, Ph.D. in Support of Patent Owner’s Response
2069	<i>Curriculum Vitae</i> of Melanie A. Simpson, Ph.D.
2070	Declaration of Gregory A. Petsko, Ph.D. in Support of Patent Owner’s Response
2071	<i>Curriculum Vitae</i> of Gregory A. Petsko, Ph.D.

Ex. No.	Description
2072	Declaration of Gary N. Cherr, Ph.D. in Support of Patent Owner's Response
2073	<i>Curriculum Vitae</i> of Gary N. Cherr, Ph.D.
2074	Declaration of James J. Moon, Ph.D. in Support of Patent Owner's Response
2075	<i>Curriculum Vitae</i> of James J. Moon, Ph.D.
2076	Transcript of the Deposition of Michael Hecht, Ph.D., August 26, 2025
2077	Transcript of the Deposition of Dr. Sheldon Park, August 7, 2025
2078	Transcript of the Deposition of Dr. Sheldon Park, August 21, 2025
2079	Koehl, P. et al., "Structure-based conformational preferences of amino acids," <i>PNAS</i> , 96(22):12524-12529 (October 26, 1999)
2080	Pommié, C. et al., "IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties," <i>Journal of Molecular Recognition</i> , 17:17-32 (2004)
2081	<i>Intentionally Left Blank</i>
2082	Kyte, J. et al., "A Simple Method for Displaying the Hydrophobic Character of a Protein," <i>Journal of Molecular Biology</i> , 157:105-132 (1982)
2083	<i>Assay Guidance Manual</i> , Eli Lilly & Company and the National Center for Advancing Translational Sciences
2084	"The Central Role of Enzymes as Biological Catalysts," NCBI Bookshelf, National Institutes of Health (accessible at https://www.ncbi.nlm.nih.gov/books/NBK9921/ , last accessed September 22, 2025)
2085	French, S. et al., "What is a Conservative Substitution?," <i>Journal of Molecular Evolution</i> , 19:171-175 (1983)

Ex. No.	Description
2086	El-Safory, N. et al., “Hyaluronidases, a group of glycosidases: Current and future perspectives,” <i>Carbohydrate Polymers</i> , 81:165-181 (2010)
2087	Lu, J. et al., “Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets,” <i>Molecular Biomedicine</i> , 6:50-77 (2025)
2088	Stern, R. et al., “Mammalian Hyaluronidases,” <i>Hyaluronan Index</i> (2000)
2089	Gmachl, M. et al., “The human sperm protein PH-20 has hyaluronidase activity,” <i>FEBS Letters</i> , 336(3):545-548 (December 1993)
2090	Gmachl, M. et al., “Bee venom hyaluronidase is homologous to a membrane protein of mammalian sperm,” <i>PNAS USA</i> , 90:3569-3573 (April 1993)
2091	Davies, G. et al., “Structures and mechanisms of glycosyl hydrolases,” <i>Current Biology</i> , 3:853-859 (1995)
2092	Marković-Housley, Z. et al., “Crystal Structure of Hyaluronidase, a Major Allergen of Bee Venom,” <i>Structure</i> , 8:1025-1035 (October 2000)
2093	U.S. Patent No. 8,343,487 B2 to Baker et al., issued January 1, 2013
2094	Thermo Scientific Multidrop® 384 User Manual, Rev. 3.4, Thermo Fisher Scientific (October 2008)
2095	<i>Intentionally Left Blank</i>
2096	Frost, G. et al., “A Microtiter-Based Assay for Hyaluronidase Activity Not Requiring Specialized Reagents,” <i>Analytical Biochemistry</i> , 251:263-269 (1997)
2097	U.S. Patent Application Publication No. 2005/0260186 A1 to Bookbinder et al., published November 24, 2005

Ex. No.	Description
2098	Delpech, B. et al., “Enzyme-Linked Hyaluronectin: A Unique Reagent for Hyaluronan Assay and Tissue Location and for Hyaluronidase Activity Detection,” <i>Analytical Biochemistry</i> , 229:35-41 (1995)
2099	Takahashi, T. et al., “A fluorimetric Morgan-Elson assay method for hyaluronidase activity,” <i>Analytical Biochemistry</i> , 322:257-263 (2003)
2100	Vines, C.V. et al., “Identification of a Hyaluronic Acid (HA) Binding Domain in the PH-20 Protein That May Function in Cell Signaling,” <i>Molecular Reproduction and Development</i> , 60:542-552 (2001)
2101	Wassarman, P. et al., “Structure and Function of the Mammalian Egg Zona Pellucida,” <i>Journal of Experimental Zoology (Mol Dev Evol)</i> , 285:251-258 (1999)
2102	Yudin, A. et al., “Structure of the cumulus matrix and zona pellucida in the golden hamster: A new view of sperm interaction with oocyte-associated extracellular matrices,” <i>Cell Tissue Res</i> 251:555-564 (1988)
2103	Tollner, T. et al., “Multifunctional glycoprotein DEFB126 – a curious story of defensin-clad spermatozoa,” <i>Nature Reviews Urology</i> , Vol. 9, pp. 365-375 (July 2012)
2104	Visconti, P. et al., “The Molecular Basis of Sperm Capacitation,” <i>Journal of Andrology</i> , 19(2):242-248 (March/April 1998)
2105	Wassarman, P. et al., “A profile of fertilization in mammals,” <i>Nature Cell Biology</i> , Vol. 3, pp. E59-E64 (February 2001)
2106	Bailey, J., “Factors Regulating Sperm Capacitation,” <i>Systems Biology in Reproductive Medicine</i> , 56:334-348 (2010)
2107	Sabeur, K. et al., “The PH-20 Protein in Human Spermatozoa,” <i>Journal of Andrology</i> , 18(2):151-158 (March/April 1997)
2108	Hunnicutt, G. et al., “Sperm Surface Protein PH-20 Is Bifunctional: One Activity Is a Hyaluronidase and a Second, Distinct Activity is Required in Secondary Sperm-Zona Binding,” <i>Biology of Reproduction</i> , 55:80-86 (1996)

Ex. No.	Description
2109	Tollner, T. et al., “Beta-Defensin 126 on the Surface of Macaque Sperm Mediates Attachment of Sperm to Oviductal Epithelia,” <i>Biology of Reproduction</i> , 78:400-412 (2008)
2110	Tollner, T. et al., “Release of DEFB126 From Macaque Sperm and Completion of Capacitation Are Triggered by Conditions That Simulate Periovulatory Oviductal Fluid,” <i>Molecular Reproduction & Development</i> , 76:431-443 (2009)
2111	Yudin, A. et al., “Beta-Defensin 126 on the Cell Surface Protects Sperm from Immunorecognition and Binding of Anti-Sperm Antibodies,” <i>Biology of Reproduction</i> , 73:1243-1252 (2005)
2112	Yudin, A. et al., “The Carbohydrate Structure of DEFB126, the Major Component of the Cynomolgus Macaque Sperm Plasma Membrane Glycocalyx,” <i>Journal of Membrane Biology</i> , 207:119-129 (2005)
2113	Tollner, T. et al., “A Common Mutation in the Defensin DEFB126 Causes Impaired Sperm Function and Subfertility,” <i>Science Translational Medicine</i> , 3(92):1-9 (2011), with erratum
2114	Frayne, J. et al., “The potential use of sperm antigens as targets for immunocontraception; past, present and future,” <i>Journal of Reproductive Immunology</i> , 43:1-33 (1999)
2115	Yanagimachi, R., “Acceleration of the Acrosome Reaction and Activation of Guinea Pig Spermatozoa by Detergents and Other Reagents,” <i>Biology of Reproduction</i> , 13:519-526 (1975)
2116	Chamley, L. et al., “Antisperm antibodies and conception,” <i>Seminars in Immunopathology</i> , 29:169-184 (2007)
2117	Kremer, J. et al., “The significance of antisperm antibodies for sperm-cervical mucus interaction,” <i>Human Reproduction</i> , 7(6):781-784 (1992)
2118	Primakoff, P. et al., “A Map of the Guinea Pig Sperm Surface Constructed with Monoclonal Antibodies,” <i>Developmental Biology</i> , 98:417-428 (1983)

Ex. No.	Description
2119	Myles, D. et al., “Localized Surface Antigens of Guinea Pig Sperm Migrate to New Regions Prior to Fertilization,” <i>The Journal of Cell Biology</i> , 99:1634-1641 (1984)
2120	Chan, C. et al., “Identification of Linear Surface Epitopes on the Guinea Pig Sperm Membrane Protein PH-20,” <i>Life Sciences</i> , 64(22):1989-2000 (1999)
2121	Ganesan, R. et al., “Structural and mechanistic insight into how antibodies inhibit serine proteases,” <i>Biochemistry Journal</i> , 430:179-189 (2010)
2122	Mestecky, J. et al., “Mucosal Immune System of the Human Genital Tract,” <i>The Journal of Infectious Diseases</i> , 179(Suppl 3):S470-S474 (1999)
2123	<i>Intentionally Left Blank</i>
2124	<i>Intentionally Left Blank</i>
2125	<i>Intentionally Left Blank</i>
2126	Suri, A., “Contraceptive vaccines targeting sperm,” <i>Expert Opinion on Biological Therapy</i> , 5(3):381-392 (2005)
2127	Morrow, R. et al., “Sustained release of proteins from a modified vaginal ring device,” <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 77:3-10 (2011)
2128	Hussain, A. et al., “The vagina as a route for systemic drug delivery,” <i>Journal of Controlled Release</i> , 103:301-313 (2005)
2129	Veazey, R. et al., “Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120,” <i>Nature Medicine</i> , 9(3):343-346 (2003)
2130	Baloglu, E. et al., “Strategies to Prolong the Intravaginal Residence Time of Drug Delivery Systems,” <i>Journal of Pharmaceutical Science</i> , 12(3):312-336 (2009)

Ex. No.	Description
2131	Suarez, S. et al., “Sperm transport in the female reproductive tract,” <i>Human Reproduction Update</i> , 12(1):23-37 (2006)
2132	Cauci, S. et al., “Combination of vaginal pH with vaginal sialidase and prolidase activities for prediction of low birth weight and preterm birth,” <i>American Journal of Obstetrics and Gynecology</i> , 192:489-496 (2005)
2133	Flori, F. et al., “Menstrual cycle–related sialidase activity of the female cervical mucus is associated with exosome-like vesicles,” <i>Fertility and Sterility</i> , 88(Suppl 2):1212-1219 (October 2007)
2134	Mestecky, J. et al., “Antibody-mediated protection and the mucosal immune system of the genital tract: relevance to vaccine design,” <i>Journal of Reproductive Immunology</i> , 85:81-85 (2010)
2135	Kim, S. et al., “Antibody Engineering for the Development of Therapeutic Antibodies,” <i>Molecules and Cells</i> , 20(1):17-29 (2005)
2136	Lardner, A., “The effects of extracellular pH on immune function,” <i>Journal of Leukocyte Biology</i> , 69:522-530 (April 2001)
2137	Lipman, N. et al., “Monoclonal Versus Polyclonal Antibodies: Distinguishing Characteristics, Applications, and Information Resources,” <i>ILAR Journal</i> , 46(3):258-268 (2005)
2138	Rhee, J. et al., “Mucosal vaccine adjuvants update,” <i>Clinical and Experimental Vaccine Research</i> , 1:50-63 (2012)
2139	Lycke, N., “Recent progress in mucosal vaccine development: potential and limitations,” <i>Nature Review</i> , 12:592-605 (August 2012)
2140	Rudin, A. et al., “Differential Kinetics and Distribution of Antibodies in Serum and Nasal and Vaginal Secretions after Nasal and Oral Vaccination of Humans,” <i>Infection and Immunity</i> , 66(7):3390-3396 (July 1998)

Ex. No.	Description
2141	Wu, H. et al., “Generation of Female Genital Tract Antibody Responses by Local or Central (Common) Mucosal Immunization,” <i>Infection and Immunity</i> , 68(10):5539-5545 (October 2000)
2142	Russell, M., “Immunization for Protection of the Reproductive Tract: A Review,” <i>American Journal of Reproductive Immunology</i> , 47:265-268 (2002)
2143	Uppada, S. et al., “Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of <i>Yersinia pestis</i> coupled to palmitate in mice,” <i>Vaccine</i> , 29:9352-9360 (2011)
2144	<i>Intentionally Left Blank</i>
2145	Gallichan, W. et al., “Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus,” <i>Vaccine</i> , 13(6):1589-1595 (1995)
2146	Johansson, E. et al., “Antibodies and Antibody-Secreting Cells in the Female Genital Tract after Vaginal or Intranasal Immunization with Cholera Toxin B Subunit or Conjugates,” <i>Infection and Immunity</i> , 66(2):514-520 (February 1998)
2147	Bergquist, C. et al., “Intranasal Vaccination of Humans with Recombinant Cholera Toxin B Subunit Induces Systemic and Local Antibody Responses in the Upper Respiratory Tract and the Vagina,” <i>Infection and Immunity</i> , 65(7):2676-2684 (July 1997)
2148	Neto, H. et al., “Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children,” <i>The Pediatric Infectious Disease Journal</i> , 28(5):365-371 (May 2009)
2149	Rhorer, J. et al., “Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials,” <i>Vaccine</i> , 27:1101-1110 (2009)

Ex. No.	Description
2150	Mielcarek, N., “Genital Antibody Responses in Mice after Intranasal Infection with an Attenuated Candidate Vector Strain of <i>Bordetella pertussis</i> ,” <i>Infection and Immunity</i> , 68(2):485-491 (February 2000)
2151	Houghton, A., “Immune recognition of self in immunity against cancer,” <i>The Journal of Clinical Investigation</i> , 114(4):468-471 (August 2004)
2152	Wan, Y. et al., “Prepared and screened a modified TNF- α molecule as TNF- α autovaccine to treat LPS induced endotoxic shock and TNF- α induced cachexia in mouse,” <i>Cellular Immunology</i> , 246:55-64 (2007)
2153	Dieudé, M. et al., “Autoantibodies to heat shock protein 60 promote thrombus formation in a murine model of arterial thrombosis,” <i>Journal of Thrombosis and Haemostasis</i> , 7:710-719 (2009)
2154	Oliver, A. et al., “Rat and Human Myelin Oligodendrocyte Glycoproteins Induce Experimental Autoimmune Encephalomyelitis by Different Mechanisms in C57BL/6 Mice,” <i>The Journal of Immunology</i> , 171(1):462-468 (2003)
2155	Trentham, D. et al. “Autoimmunity to Type II Collagen: An Experimental Model of Arthritis,” <i>The Journal of Experimental Medicine</i> , 146:857-868 (1977)
2156	Courtenay, J. et al., “Immunisation against heterologous type II collagen induces arthritis in mice,” <i>Nature</i> , 283:666-668 (1980)
2157	Tomita, M. et al., “Hybridoma technologies for antibody production,” <i>Immunotherapy</i> , 3(3):371-380 (2011)
2158	Excerpts from <i>Antibody Methods and Protocols</i> , Proetz G. and Ebersbach H. eds., Humana Press (2012) (including Zhang, C., “Hybridoma Technology for the Generation of Monoclonal Antibodies,” Chapter 7; and Lee, E. et al., “The Application of Transgenic Mice for Therapeutic Antibody Discovery,” Chapter 8)

Ex. No.	Description
2159	Zeitlin, L. et al., “Topically Applied Human Recombinant Monoclonal IgG1 Antibody and Its Fab and F(ab’) ₂ Fragments Protect Mice from Vaginal Transmission of HSV-2,” <i>Virology</i> , 225:213-215 (1996)
2160	Sherwood, J. et al., “Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes,” <i>Nature Biotechnology</i> , 14:468-471 (April 1996)
2161	Veselinovic, M. et al., “Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model,” <i>Virology</i> , 432:505-510 (2012)
2162	Schweitzer, M. et al., “Microscopic, chemical and molecular methods for examining fossil preservation,” <i>Comptes Rendus Palevol</i> , 7:159-184 (2008)
2163	National Medal of Science in Medicine Citation for Gregory Petsko, 2022 (accessible at https://nationalmedals.org/laureate/gregory-petsko/?amp=1 , last accessed September 19, 2025)
2164	Petsko, G., et al., <i>Protein Structure and Function</i> , New Science Press (2004)
2165	U.S. Patent Application Publication No. 2010/0143457 A1 to Wei et al., published June 10, 2010
2166	Petsko Patent Analysis Data
2167	Huang, C. et al., “Effect of sublingual administration with a native or denatured protein allergen and adjuvant CpG oligodeoxynucleotides or cholera toxin on systemic TH2 immune responses and mucosal immunity in mice,” <i>Annals of Allergy, Asthma, and Immunology</i> , 99:443-452 (November 2007)
2168	Profile of Gregory A. Petsko, American Academy of Arts and Sciences (accessible at https://www.amacad.org/person/gregory-petsko , last accessed September 22, 2025)

Ex. No.	Description
2169	“BLAST Topics,” National Institutes of Health (accessible at https://blast.ncbi.nlm.nih.gov/doc/blast-topics , last accessed September 22, 2025)
2170	Chain, E. et al., “Identity of Hyaluronidase and Spreading Factor,” <i>British Journal of Experimental Pathology</i> , 21(6):324-338 (1940)
2171	Tollner, T. et al., “Macaque Sperm Release ESP13.2 and PSP94 During Capacitation: The Absence of ESP13.2 Is Linked to Sperm-Zona Recognition and Binding,” <i>Molecular Reproduction and Development</i> , 69:325-337 (2004)
2172	Yudin, A. et al., “Characterization of the active site of monkey sperm hyaluronidase,” <i>Reproduction</i> , 121:735-743 (2001)
2173	Yudin, A. et al., “PH-20 but Not Acrosin Is Involved in Sperm Penetration of the Macaque Zona Pellucida,” <i>Molecular Reproduction and Development</i> , 53:350-362 (1999)
2174	Errata from Park Deposition (introduced during Park deposition and marked by court reporter as “Park 2068”)
2175	Mutational Analysis Table, 2024-11-7, Native Excel File (introduced during Park deposition and marked by court reporter as “Park 2069”)
2176	Mutational Analysis Table, 2024-11-7, PDF File (introduced during Park deposition and marked by court reporter as “Park 2070”)
2177	E-mail Correspondence dated August 14, 2025
2178	1LOH pdb file
2179	1FCV pdb file
2180	2PE4 pdb file
2181	8SMN pdb file
2182	E324A Swiss Model

Ex. No.	Description
2183	E324D Swiss Model
2184	E324H Swiss Model
2185	E324M Swiss Model
2186	E324N Swiss Model
2187	E324R Swiss Model
2188	E324S Swiss Model
2189	N47A_N219A_E324D Swiss Model
2190	N47A_N131A_E324D Swiss Model
2191	PH20 Swiss Model
2192	N131A_N219A_E324D Swiss Model
2193	N47A_N131A_N219A_E324D Swiss Model
2194	N47A_N219A_E324N Swiss Model
2195	N47A_N131A_E324N Swiss Model
2196	N47A_N131A_N219A_E324N Swiss Model
2197	N131A_N219A_E324N Swiss Model
2198	N47A_N219A_E324R Swiss Model
2199	N47A_N131A_E324R Swiss Model
2200	N47A_N131A_N219A_E324R Swiss Model
2201	N131A_N219A_E324R Swiss Model
2202	Orangutan_E324D Swiss Model
2203	Orangutan_E324N Swiss Model

Ex. No.	Description
2204	Orangutan_E324R Swiss Model
2205	Chimpanzee_E324D Swiss Model
2206	Chimpanzee_E324N Swiss Model
2207	Chimpanzee_E324R Swiss Model
2208	Gibbon_E324D Swiss Model
2209	Gibbon_E324N Swiss Model
2210	Gibbon_E324R Swiss Model
2211-2399	<i>Intentionally Left Blank</i>
2400	Merck & Co., Inc. Form 10-Q, Securities and Exchange Commission, November 5, 2025
2401	E-mail Correspondence between Counsel for Petitioner and Patent Owner, January 6, 2026 (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2402	MERCK_PGR00006 - 30November2023 Merck 031988 Master Agreement - executed 4932-6153-3216 1_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2403	MERCK_PGR00056 - MSA - Term 4 - Dechert LLP_Signed_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2404	MERCK_PGR00467 - Mark Stewart Offer Letter_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2405	MERCK_PGR00052 - Hecht Engagement Letter (7-19)_Signed (Redacted)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)

Ex. No.	Description
2406	MERCK_PGR00086 - Park Engagement Letter with signature - sjp (redacted)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2407	“Executive team,” MSD, accessible at http://www.msd.com/company-overview/leadership/executive-team/ (last accessed January 5, 2026)
2408	“Executive team,” Merck, accessible at http://www.merck.com/company-overview/leadership/executive-team/ (last accessed January 5, 2026)
2409	“Board of directors,” MSD, accessible at http://www.msd.com/company-overview/leadership/board-of-directors/ (last accessed January 5, 2026)
2410	“Board of directors,” Merck, accessible at http://www.merck.com/company-overview/leadership/board-of-directors/ (last accessed January 5, 2026)
2411	“Contact us,” MSD, accessible at http://www.msd.com/contact-us/ (last accessed January 5, 2026)
2412	“Contact us,” Merck, accessible at http://www.merck.com/contact-us/ (last accessed January 5, 2026)
2413	“Who we are,” MSD, accessible at http://www.msd.com/company-overview/ (last accessed January 5, 2026)
2414	“Who we are,” Merck, accessible at http://www.merck.com/company-overview/ (last accessed January 5, 2026)
2415	Merck & Co., Inc. Form 10-K, Securities and Exchange Commission, February 25, 2025
2416	USPTO OED Practitioner Search - Mark J. Stewart
2417	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00240 (P.T.A.B.), November 30, 2023

Ex. No.	Description
2418	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00622 (P.T.A.B.), March 4, 2024
2419	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00623 (P.T.A.B.), March 4, 2024
2420	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00624 (P.T.A.B.), March 4, 2024
2421	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00625 (P.T.A.B.), March 4, 2024
2422	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00647 (P.T.A.B.), March 13, 2024
2423	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00648 (P.T.A.B.), March 13, 2024
2424	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00649 (P.T.A.B.), March 13, 2024
2425	Petition for <i>Inter Partes</i> Review, <i>Merck Sharp & Dohme LLC v. The Johns Hopkins University</i> , IPR2024-00650 (P.T.A.B.), March 13, 2024
2426	MERCK_PGR00035 - 20250813 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2427	MERCK_PGR00042 - Dechert T360 Halozyme - 202500327_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2428	MERCK_PGR00045 - FW_Atn_Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Nov 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)

Ex. No.	Description
2429	MERCK_PGR00049 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_1 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2430	MERCK_PGR00465 - Mark Stewart Payroll Statement for Dec 12 2025_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2431	MERCK_PGR00001 - Workday - Ginkel Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2432	MERCK_PGR00002 - Workday - Lally Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2433	MERCK_PGR00003 - Workday - Majchrzak Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2434	MERCK_PGR00004 - Workday - Stewart Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2435	MERCK_PGR00005 - Workday - Su Organization Screen Shot (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2436	MERCK_PGR00036 - 20250903 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2437	MERCK_PGR00037 - 20251001 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2438	MERCK_PGR00038 - 20251203 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2439	MERCK_PGR00040 - 20251215 Payment Remittance_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2440	MERCK_PGR00046 - FW_Atn_Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Oct 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)

Ex. No.	Description
2441	MERCK_PGR00047 - FW_ Attn_ Accounts Receivable Dept - PAYMENT REMITTANCE DETAIL (Sept 2025)_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2442	MERCK_PGR00048 - Halozyme - 202000447 - Invoice IN00125072310 Review History (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2443	MERCK_PGR00050 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_2 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2444	MERCK_PGR00051 - Halozyme - 202000447 - Invoices 5_1_2024-12_22_2025_3 of 3_Redacted (CONFIDENTIAL – PROTECTIVE ORDER MATERIAL)
2445	By-Laws of Merck & Co., Inc., Effective as of November 19, 2024

As authorized by email on December 19, 2025, Patent Owner Halozyme, Inc., moves for additional discovery from Merck Sharp & Dohme LLC (“MSD”).

I. INTRODUCTION: DISCOVERY IS WARRANTED

The Petition here names Petitioner MSD as the *sole* real party-in-interest (“RPI”). *See, e.g.*, Pet. at 6. But information obtained by Halozyme indicates that Merck & Co., Inc. (“Merck & Co.”), MSD’s corporate parent, should have been named as an RPI. Unredacted versions of documents Halozyme seeks via this motion are highly relevant because, as held in *Corning*, a petition that fails to identify all RPI cannot be considered by the Board. *Corning Optical Commc’ns RF, LLC v. PPC Broadband, Inc.*, IPR2014-00440, Paper 68 at 24 (P.T.A.B. Aug. 18, 2015) (designated precedential Oct. 28, 2025) (“*Corning*”).

Even if Petitioner chooses later to amend its Petition to correctly name all RPI, under *Corning*, the Petition will be given a new filing date, which will render it ineligible for PGR review because that date would be after the statutory deadline to file a PGR. 37 C.F.R. § 42.206; *see Corning* at 23-25. In that situation, as in *Corning*, the Board should dismiss the Petition for failure to name all RPI, vacate the Decision on Institution, and terminate the proceeding.¹ *Corning* at 23-25.

In this motion, Halozyme seeks targeted discovery from MSD as it relates to

¹ Halozyme expects to request leave to file a motion to dismiss the Petition after the additional discovery process concludes.

RPI. After previously refusing to produce any documents, and only after this motion was authorized, Petitioner reversed course and produced documents containing *extensive* unjustified redactions. This motion merely seeks production of unredacted versions of already produced documents. *See* EX2402-EX2406, EX2426-EX2430, EX2436-EX2441, and EX2443-EX2444.

As discussed below, information available so far indicates, beyond a mere possibility or speculation, that the requested additional discovery is likely to uncover evidence confirming that at least MSD's parent company, Merck & Co., is an unnamed RPI. *See infra* 8-9. For instance, Petitioner admitted after being pressed by Halozyme that it had "[REDACTED]
[REDACTED]
[REDACTED]" EX2401 at 5 (Dec. 30, 2025 email). Yet Petitioner still refuses to produce unredacted versions of the already produced documents. Those documents and other evidence will likely reveal blurred corporate lines between MSD and Merck & Co., as well as the ability of Merck & Co. to control and fund this PGR proceeding. *Id.*; *Corning* at 15.

Good cause exists for the Board to grant this motion, which merely asks the Board to require Petitioner to produce unredacted copies of documents it has already produced. It is clear from redacted versions already that, at minimum, unredacted versions of these documents are likely relevant to the issue of blurred

lines between MSD and Merck & Co. Unredacted versions of these documents may be produced under seal, per the Board's Default Protective Order, already agreed to by the parties. 37 C.F.R. § 42.224(a); 35 U.S.C. § 326(a)(1), (5).

II. BACKGROUND: PETITIONER HAS REFUSED TO PROVIDE UNREDACTED VERSIONS OF RELEVANT DOCUMENTS

Petitioner has serially filed 15 PGR Petitions challenging 15 related patents owned by Halozyme. All 15 Petitions name MSD as the *sole* RPI. *See, e.g.*, Pet. at 6. Meanwhile, after several of the PGR Petitions were filed, Halozyme filed a lawsuit alleging that MSD's product, KEYTRUDA QLEX™, a second generation KEYTRUDA® product, infringes 12 of Halozyme's patents now involved in these PGR proceedings. EX2058.

On October 28, 2025, the USPTO Director designated *Corning* precedential for its holding that petitions failing to identify all RPI "have not met the requirements" of 35 U.S.C. § 322(a)(2), "and, therefore, are incomplete and cannot be considered." *Corning* at 24. Once *Corning* was designated precedential, rendering the RPI issue outcome-dispositive, Halozyme immediately investigated the issue and contacted Petitioner seeking relevant discovery. Petitioner refused to produce any discovery. Halozyme promptly contacted the Board and sought authorization for this motion, which the Board granted. EX2401 at 2-3.

After that authorization, Petitioner finally provided requested information and *heavily redacted* documents on December 23, 2025, while again maintaining

that Merck & Co. is not an RPI. EX2401 at 7-10 (Dec. 23, 2025 email).

Thereafter, Halozyme has repeatedly requested unredacted versions of the produced documents, and Petitioner has repeatedly refused. EX2401 at 2-3, 5. In doing so, Petitioner has effectively asserted that Halozyme must accept that the redacted portions are irrelevant simply because Petitioner says so.

III. ARGUMENT: PETITIONER SHOULD PROVIDE UNREDACTED VERSIONS OF ALL DOCUMENTS

In this motion, Halozyme requests *unredacted* versions of *all* documents already produced by Petitioner. Some of the most relevant and heavily redacted documents include, for example:

- Engagement Letters for Petitioner's two outside law firms, with Guideline attachments and exhibits, which currently include heavy redactions to entire sections (~75% of ~30 pages), *see* EX2402, EX2403 (MERCK_PGR00006-034 and MERCK_PGR00056-85);
- Retainer letters for Petitioner's experts Dr. Hecht (MERCK_PGR00052-055) and Dr. Park (MERCK_PGR00086-89), which currently redact entire sections (in 2 out of 3 pages). *See* EX2405, EX2406.
- Employment Offer Letter of Petitioner's back-up counsel Mark Stewart. which currently includes heavy redactions to entire sections (>70% of 7 pages), *see* EX2404 (MERCK_PGR00467-473);

Halozyme requests unredacted versions of these and other documents that Petitioner produced on December 23, 2025. *See* EX2402-EX2406, EX2426-EX2430, EX2436-EX2441, and EX2443-EX2444.

Notwithstanding Petitioner's conclusory statements to Halozyme, many of the redacted portions of the produced documents appear highly relevant and non-privileged. For instance, Petitioner admitted for the first time in its December 30, 2025 email that Mr. Stewart's Offer Letter "[REDACTED]

[REDACTED]" EX2401 at 5 (Dec. 30, 2025 email). Despite Halozyme's request, Petitioner has not produced an unredacted version of even this portion of his Offer Letter.

As other examples, the two outside counsel engagement agreements include sections [REDACTED]

[REDACTED]. It is likely that these sections contain information that bears on the issue of RPI; for example, one or more of these sections is likely to identify or refer to MSD affiliates or corporate partners. As a matter of fairness, Halozyme needs to determine for itself whether these redacted sections are relevant to the issue of RPI and not merely depend on Petitioner's allegations that they are not.

Halozyme thus requests in this motion unredacted versions of the documents (*see* EX2402-EX2406, EX2426-EX2430, EX2436-EX2441, EX2443-EX2444), except to the extent the redacted information is privileged, reflects specific dollar amounts in relation to payment remittances or Mr. Stewart's compensation, or contains information entirely personal to Mr. Stewart, such as his social security

number or home address. EX2401 at 3-4 (Jan. 1, 2026 email). To the extent any information is redacted for these reasons, Halozyme also requests that Petitioner provide a log identifying each document by Bates number, and the exact basis for each individual redaction. *Id.*

When attempting to justify its heavy redactions, Petitioner cited rules and Board decisions that merely discuss when additional discovery is warranted at all. Nothing in those rules or Board decisions authorizes extensive redactions of the type that Petitioner applied here. EX2401 at 5 (Dec. 30, 2025 email). For example, 37 C.F.R. § 42.51(b)(2) and § 42.224 merely state in relevant part that additional discovery “is limited to evidence directly related to factual assertions advanced by either party in the proceeding.” But Halozyme’s request *is* directly related to a factual assertion it advances, i.e., the Petition fails to name all RPI because it should have named Merck & Co. in addition to MSD.

The two Board decisions Petitioner cited are also inapposite. EX2401 at 2-3 (Jan. 2, 2026 email) (citing *Unified Patents, LLC v. American GNC Corp.*, IPR2019-00505, Paper 20 (PTAB Apr. 12, 2019) and *New World Medical, Inc. v. MicroSurgical Tech., Inc.*, IPR2020-01573, Paper 13 (PTAB Dec. 10, 2020)). *Unified Patents* does not address whether a producing party can unilaterally redact portions of a document it deems to be irrelevant in an otherwise relevant document. And *New World Medical* noted that, in contrast to the situation here,

“very little [was] masked by redaction” and that “[a]lmost all of the language of the license agreement is accessible, with only the most specific financial terms redacted.” *Id.* at 6. These specific financial terms had no bearing on RPI. *Id.* Here, on the other hand, whole sections of many documents are redacted.

It is clear from the very cases and quotes that Petitioner selects that these Board decisions do not stand, at all, for the proposition that a party may redact *ad libitum* from discovery it produces. In fact, no Board rule or decision supports Petitioner’s heavy redactions. Indeed, it would frustrate the purpose of discovery, not to mention invite gamesmanship, to allow a party to selectively redact information it judges is irrelevant in otherwise relevant documents. Moreover, especially here, where the parties have already agreed that the production will be covered by the Board’s default protective order, there is no justification merely because the redacted information is allegedly “sensitive.”

The facts here are strikingly similar to *Corning*’s in that Petitioner continues to maintain that it is the only RPI. Even after *Corning* became precedential and Halozyme raised the issue, Petitioner has insisted that its parent company, Merck & Co., is not an RPI. This posture is in stark contrast to the facts in *Adello* where the petitioner admitted its error, stated an RPI was “inadvertently omitted,” and asked to correct the error soon after Patent Owner raised the issue. *Adello Biologics LLC v. Amgen Inc.*, PGR2019-00001, Paper 11 at 2 (P.T.A.B. Feb. 14,

2019). In *Adello*, the Board noted that facts suggested “the omission may have been a human error,” and petitioner was “attempting to be diligent in updating the mandatory notices” upon discovering that error. *Id.* at 5. By contrast, MSD has doubled down on its story that its parent company is not an RPI.

A. HALOZYME’S DISCOVERY REQUESTS SATISFY THE *GARMIN* FACTORS AND GOOD CAUSE EXISTS FOR THE REQUESTED DISCOVERY.

Halozyme’s requests are warranted because all five *Garmin* factors are met. See *Garmin International, Inc. v. Cuozzo Speed Technologies LLC*, IPR2012-00001, Paper 26 at 6-7 (P.T.A.B. Mar. 5, 2013) (precedential), as modified by *Bloomberg, Inc. v. Market-Alerts Pty, Ltd.*, CBM2013-00005, Paper 32 at 4 (P.T.A.B. May 29, 2013) (precedential); 37 CFR § 42.224(a).

1. *Garmin* Factor 1: More Than a Possibility And Mere Allegation that Useful Information Will Be Found

Under the first *Garmin* factor, “the requester of information should already be in possession of a threshold amount of evidence or reasoning tending to show beyond speculation that something useful will be uncovered.” IPR2012-00001, Paper 26 at 7. MSD has represented to the Board that MSD is the *sole* RPI in these proceedings. Pet. at 6. Information available so far, however, indicates there is a significant likelihood that unredacted versions of documents Petitioner has produced will confirm Merck & Co. is an unnamed RPI.

Examples of already available information include, for example:

- Merck & Co.’s November 5, 2025 public SEC statements and ByLaws: (1) attributing the filing and funding of the PGRs to itself; (2) indicating Merck & Co. indemnifies MSD for its expenses in “any . . . suit,” such these PGRs; (3) specifying that Merck & Co. holds an exclusive license to and pays royalties on components of KEYTRUDA QLEX™, at issue in related litigation, EX2400 at 6, 8, 21, 24-26; EX2445 at 17-18;
- Public websites indicating that MSD and Merck & Co. have the exact same executive leadership (including CEO) and Board of Directors, as well as address, phone number, and business hours, EX2407–EX2414;
- Mark Stewart, back up counsel for Petitioner, listing on an OED document that he practices on behalf of MSD and Merck & Co., EX2416; and
- MSD LLC naming Merck & Co. as an RPI in IPR proceedings related to KEYTRUDA®, a precursor to KEYTRUDA QLEX™, relevant here. EX2417–EX2425.

Consistent with this information, many redacted portions of documents produced by Petitioner appear highly relevant, such as large portions of Mr. Stewart’s Offer Letter, outside counsel engagement letters, and expert retainer agreements.

Petitioner has argued that these redacted sections are “not directly related to the RPI analysis.” EX2401 at 2 (Jan. 2, 2026 email). But surely, there is more than a mere possibility that within, for example, [REDACTED]

[REDACTED]

sections of the representation letter, there is discussion of corporate affiliations

having a relationship to this proceeding. The same goes for the other sections redacted by Petitioner. Again, Petitioner provides no valid justification for picking and choosing what to redact. Halozyme should be allowed to judge these sections, within otherwise relevant documents, for itself.

2. *Garmin* Factor 2: No Request for Litigation Positions and Underlying Basis

The request for unredacted versions of documents that Petitioner has provided does not seek MSD's or Merck & Co.'s litigation positions or basis.

3. *Garmin* Factor 3: No Ability To Generate Equivalent Information By Other Means

Halozyme is not able to obtain equivalent information to that redacted in the produced documents by other means. Highly relevant information Halozyme seeks is in MSD's possession and control and is not publicly available.

4. *Garmin* Factors 4 and 5: Requests Are Easily Understandable and Not Overly Burdensome To Answer

Halozyme's request for unredacted documents is easily understandable and are not overly burdensome. Petitioner can simply unredact information in documents it has already provided.

IV. CONCLUSION

The *Garmin* factors strongly support granting additional discovery.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.
Registration No. 39,967
Attorney for Patent Owner

Date: January 6, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600

CERTIFICATE OF SERVICE (37 C.F.R. § 42.6(e))

I certify that the above-captioned **PATENT OWNER'S MOTION FOR ADDITIONAL DISCOVERY** and Exhibits 2400-2445 were served in their entireties on January 6, 2026, upon the following parties via electronic mail:

Jeffrey P. Kushan (Lead Counsel) jkushan@sidley.com
Leif Peterson (Back-up Counsel) leif.peterson@sidley.com
Sue Wang (Back-up Counsel) sue.wang@sidley.com
Katherine A. Helm (Back-up Counsel) khelm@dechert.com
Blaine Hackman (Back-up Counsel) Blaine.Hackman@dechert.com
Amy Mahan (Back-up Counsel) amy.mahan@sidley.com
Christine M. Engen (Back-up Counsel) christine.engen@sidley.com
Amit Bhatla (Back-up Counsel) abhatla@sidley.com
Brian M. Goldberg (Back-up Counsel) Brian.Goldberg@dechert.com
Mark Stewart (Back-up Counsel) mark.stewart@merck.com
HalozymePGRs@sidley.com

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX PLLC

/Eldora L. Ellison/

Eldora L. Ellison, Ph.D.
Registration No. 39,967
Attorney for Patent Owner

Date: January 6, 2026

1101 K Street, NW, 10th Floor
Washington, DC 20005
(202) 371-2600